Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
John Bisi(Argos Therapeutics (United States)), Jay C. Strum(Argos Therapeutics (United States))
Cited by 58
Related Papers
No related papers found
Powered by citation graph analysis